KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dynavax Technologies (DVAX) EBITDA (2016 - 2025)

Historic EBITDA for Dynavax Technologies (DVAX) over the last 17 years, with Q3 2025 value amounting to $21.3 million.

  • Dynavax Technologies' EBITDA rose 11098.0% to $21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 19506.38%. This contributed to the annual value of -$4.1 million for FY2024, which is 8886.79% up from last year.
  • According to the latest figures from Q3 2025, Dynavax Technologies' EBITDA is $21.3 million, which was up 11098.0% from $14.4 million recorded in Q2 2025.
  • Dynavax Technologies' EBITDA's 5-year high stood at $128.2 million during Q2 2022, with a 5-year trough of -$30.2 million in Q1 2023.
  • For the 5-year period, Dynavax Technologies' EBITDA averaged around $20.5 million, with its median value being $10.1 million (2024).
  • In the last 5 years, Dynavax Technologies' EBITDA surged by 129802.66% in 2022 and then crashed by 19832.59% in 2023.
  • Over the past 5 years, Dynavax Technologies' EBITDA (Quarter) stood at $80.7 million in 2021, then dropped by 21.78% to $63.1 million in 2022, then tumbled by 113.45% to -$8.5 million in 2023, then surged by 80.78% to -$1.6 million in 2024, then soared by 1403.37% to $21.3 million in 2025.
  • Its EBITDA was $21.3 million in Q3 2025, compared to $14.4 million in Q2 2025 and -$23.6 million in Q1 2025.